Homocysteine, frailty, and all-cause mortality in older men: The health in men study

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 5, 2013, Pages 590-598

  Wong, Yuen Y E ^a,b,c   Almeida, Osvaldo P ^a,d   McCaul, Kieran A ^a,b   Yeap, Bu B ^b,e   Hankey, Graeme J ^c   Flicker, Leon ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e FREMANTLE HOSPITAL   (Australia)

Author keywords

All cause mortality.; Frailty; Homocysteine

Indexed keywords

HOMOCYSTEINE;

AGED; ARTICLE; BLOOD; CAUSE OF DEATH; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; METHODOLOGY; MORTALITY; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; PROSPECTIVE STUDIES;

MLCS; MLOWN;

EID: 84876239476     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls211     Document Type: Article

References (45)

1. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54:991-1001.
2. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-M156.
3. Jones D, Song X, Mitnitski A, Rockwood K. Evaluation of a frailty index based on a comprehensive geriatric assessment in a population based study of elderly Canadians. Aging Clin Exp Res. 2005;17:465-471.
4. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging. 2008;12:29-37.
5. Abellan van Kan G, Rolland YM, Morley JE, Vellas B. Frailty: toward a clinical defnition. J Am Med Dir Assoc. 2008;9:71-72.
6. Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab. 2010;95:3165-3172.
7. Samper-Ternent R, Karmarkar A, Graham J, Reistetter T, Ottenbacher K. Frailty as a predictor of falls in older Mexican Americans. J Aging Health. 2012;24:641-653.
8. Griebling TL. Re: accumulated frailty characteristics predict postop-erative discharge institutionalization in the geriatric patient. J Urol. 2011;186:2304-2305.
9. Masel MC, Graham JE, Reistetter TA, Markides KS, Ottenbacher KJ. Frailty and health related quality of life in older Mexican Americans. Health Qual Life Outcomes. 2009;7:70.
10. Wilson JF. Frailty-and its dangerous effects-might be preventable. Ann Intern Med. 2004;141:489-492.
11. Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syn-drome. Am J Med. 2007;120:748-753.
12. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
13. Green R. Indicators for assessing folate and vitamin B12 status and for monitoring the effcacy of intervention strategies. Food Nutr Bull. 2008;29:S52-S63; discussion S64-S56.
14. Depeint F, Bruce WR, Shangari N, Mehta R, O'Brien PJ. Mtochondrial function and toxicity: role of B vitamins on the one-carbon transfer pathways. Chem Biol Interact. 2006;163:113-132.
15. Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspec-tives. J Nutr Health Aging. 2008;12:433-450.
16. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol. 2000;20: 1182-1184.
17. Manolescu BN, Oprea E, Farcasanu IC, Berteanu M, Cercasov C. Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochim Pol. 2010;57:467-477.
18. Carluccio MA, Ancora MA, Massaro M, et al. Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxi-dants. Am J Physiol Heart Circ Physiol. 2007;293:H2344-H2354.
19. Zhang C, Cai Y, Adachi MT, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem. 2001;276:35867-35874.
20. Perez FP, Ilie JI, Zhou X, Feinstein D, Jurivich DA. Pathomolecular effects of homocysteine on the aging process: a new theory of aging. Med Hypotheses. 2007;69:149-160.
21. Gallucci M, Ongaro F, Amici GP, Regini C. Frailty, disability and survival in the elderly over the age of seventy: evidence from "The Treviso Longeva (TRELONG) Study". Arch Gerontol Geriatr. 2009;48:281-283.
22. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort profle: the health in men study (HIMS). Int J Epidemiol. 2009;38:48-52.
23. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health sur-vey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
24. Lopez D, Flicker L, Dobson A. Validation of the frail scale in a cohort of older Australian women. J Am Geriatr Soc. 2012;60:171-173.
25. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health. 1999;23:453-459.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: develop-ment and validation. J Chronic Dis. 1987;40:373-383.
27. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. Clin Chem. 1999;45:569-571.
28. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular fltration rate. Ann Intern Med. 2009;150:604-612.
29. Bartali B, Frongillo EA, Bandinelli S, et al. Low nutrient intake is an essential component of frailty in older persons. J Gerontol A Biol Sci Med Sci. 2006;61:589-593.
30. Mchelon E, Blaum C, Semba RD, Xue QL, Ricks MO, Fried LP. Vitamin and carotenoid status in older women: associations with the frailty syndrome. J Gerontol A Biol Sci Med Sci. 2006;61:600-607.
31. Semba RD, Bartali B, Zhou J, Blaum C, Ko CW, Fried LP. Low serum micronutrient concentrations predict frailty among older women living in the community. J Gerontol A Biol Sci Med Sci. 2006;61:594-599.
32. Matteini AM, Walston JD, Fallin MD, et al. Markers of B-vitamin defciency and frailty in older women. J Nutr Health Aging. 2008;12:303-308.
33. Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K. Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci. 2010;65:377-381.
34. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755-763.
35. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136:1726S-1730S.
36. Cesari M, Penninx BW, Pahor M, et al. Infammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242-248.
37. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159:1077-1080.
38. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homocyst-eine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med. 1999;131:321-330.
39. Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001;74:130-136.
40. Dangour AD, Breeze E, Clarke R, Shetty PS, Uauy R, Fletcher AE. Plasma homocysteine, but not folate or vitamin B-12, predicts mortality in older people in the United Kingdom. J Nutr. 2008;138:1121-1128.
41. Bates CJ, Mansoor MA, Pentieva KD, Hamer M, Mishra GD. Biochemical risk indices, including plasma homocysteine, that prospectively predict mortality in older British people: the National Diet and Nutrition Survey of People Aged 65 Years and Over. Br J Nutr. 2010;104:893-899.
42. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specifc mortality: meta-analysis of 8 rand-omized trials involving 37 485 individuals. Arch Intern Med. 2010;170:1622-1631.
43. Debreceni B, Debreceni L. Why do homocysteine-lowering B vita-min and antioxidant e vitamin supplementations appear to be ineffec-tive in the prevention of cardiovascular diseases? Cardiovasc Ther. 2012;30:227-233.
44. Spence JD, Stampfer MJ. Understanding the complexity of homocyst-eine lowering with vitamins: the potential role of subgroup analyses. JAMA. 2011;306:2610-2611.
45. Hayes V, Morris J, Wolfe C, Morgan M. The SF-36 health survey questionnaire: is it suitable for use with older adults? Age Ageing. 1995;24:120-125.